应用母体PlGF及sFlt-1/PlGF比值预测胎儿生长受限与适于胎龄儿早产的前瞻性研究
该前瞻性观察性队列研究在澳大利亚一家三级妇产医院纳入320例单胎妊娠,其中适于胎龄儿141例(44.1%)、早发型胎儿生长受限83例(25.9%)、晚发型胎儿生长受限109例(30.0%),每4周检测母体血清PlGF及sFlt-1/PlGF比值。结果显示PlGF<100 ng/L和sFlt-1/PlGF比值升高对早产及诊断后1、2、3周内早产均有较强预测作用,胎儿生长受限队列中PlGF<100 ng/L时RR最高(RR 35.20,95%CI 11.48-175.46)。
要点
- 早发型胎儿生长受限队列中位PlGF为54 ng/L,适于胎龄儿为229 ng/L(p<0.001)。
- PlGF<100 ng/L和sFlt-1/PlGF比值升高对早产及诊断后1、2、3周内早产均有较强预测作用。
- 胎儿生长受限队列中PlGF<100 ng/L时早产风险RR 35.20(95%CI 11.48-175.46)。
核心结论
- 低母体PlGF水平及升高的sFlt-1/PlGF比值可能有助于预测胎儿生长受限和适于胎龄儿妊娠的早产。
研究设计与样本
- 前瞻性观察性队列研究,在澳大利亚一家三级妇产医院纳入320例单胎妊娠。
- 其中适于胎龄儿141例(44.1%)、早发型胎儿生长受限(<32+0周)83例(25.9%)、晚发型胎儿生长受限(≥32+0周)109例(30.0%)。
- 从入组至分娩每4周检测母体血清PlGF和sFlt-1/PlGF比值,采用Cox比例风险模型分析。
- 低母体PlGF水平定义为<100 ng/L;sFlt-1/PlGF比值升高定义为<28周时>5.78、≥28周时>38。
主要发现
- 早发型胎儿生长受限队列中位PlGF水平较低(54 vs 229 ng/L,p<0.001)。
- 早发型胎儿生长受限队列中位sFlt-1水平较高(2774 ng/L vs 2096 ng/L,p<0.001),sFlt-1/PlGF比值较高(35 vs 10,p<0.001)。
- PlGF<100 ng/L和sFlt-1/PlGF比值升高对早产及诊断后1、2、3周内早产均有较强预测作用。
- 在胎儿生长受限和适于胎龄儿两组中,PlGF<100 ng/L或sFlt-1/PlGF比值升高均与医学指征早产风险增加强相关。
- 胎儿生长受限队列中PlGF<100 ng/L时RR最高(RR 35.20,95%CI 11.48-175.46)。
关键数值与推荐
- 低母体PlGF水平定义为<100 ng/L。
- sFlt-1/PlGF比值升高定义为<28周时>5.78、≥28周时>38。
- 胎儿生长受限队列中PlGF<100 ng/L时早产风险RR 35.20(95%CI 11.48-175.46)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the utility of placental growth factor (PlGF) levels and the soluble fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio to predict preterm birth (PTB) for infants with fetal growth restriction (FGR) and those appropriate for gestational age (AGA). DESIGN: Prospective, observational cohort study. SETTING: Tertiary maternity hospital in Australia. POPULATION: There were 320 singleton pregnancies: 141 (44.1%) AGA, 83 (25.9%) early FGR (<32+0 weeks) and 109 (30.0%) late FGR (≥32+0 weeks). METHODS: Maternal serum PlGF and sFlt-1/PlGF ratio were measured at 4-weekly intervals from recruitment to delivery. Low maternal PlGF levels and elevated sFlt-1/PlGF ratio were defined as <100 ng/L and >5.78 if <28 weeks and >38 if ≥28 weeks respectively. Cox proportional hazards models were used. The analysis period was defined as the time from the first measurement of PlGF and sFlt-1/PlGF ratio to the time of birth or censoring. MAIN OUTCOME MEASURES: The primary study outcome was overall PTB. The relative risks (RR) of birth within 1, 2 and 3 weeks and for medically indicated and spontaneous PTB were also ascertained. RESULTS: The early FGR cohort had lower median PlGF levels (54 versus 229 ng/L, p < 0.001) and higher median sFlt-1 levels (2774 ng/L versus 2096 ng/L, p < 0.001) and sFlt-1/PlGF ratio higher (35 versus 10, p < 0.001). Both PlGF <100 ng/L and elevated sFlt-1/PlGF ratio were strongly predictive for PTB as well as PTB within 1, 2 and 3 weeks of diagnosis. For both FGR and AGA groups, PlGF <100 ng/L or raised sFlt-1/PlGF ratio were strongly associated with increased risk for medically indicated PTB. The highest RR was seen in the FGR cohort when PlGF was <100 ng/L (RR 35.20, 95% CI 11.48-175.46). CONCLUSIONS: Low maternal PlGF levels and elevated sFlt-1/PlGF ratio are potentially useful to predict PTB in both FGR and AGA pregnancies.
引用
- Hong J, Crawford K, Cavanagh E, et al. Prediction of preterm birth in growth-restricted and appropriate-for-gestational-age infants using maternal PlGF and the sFlt-1/PlGF ratio-A prospective study. BJOG. 2024. PMID: 38196326. doi:10.1111/1471-0528.17752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。